Overview

Confirmatory Study of Govorestat in CMT-SORD

Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the long-term efficacy and clinical benefit of AT-007 in patients with CMT-SORD. This randomized, double-blind study will assess the effect of govorestat compared to placebo in patients with CMT-SORD for up to 36 months.
Phase:
PHASE3
Details
Lead Sponsor:
Applied Therapeutics, Inc.